GLP-1 RT (Retatrutide)

Retatrutide is a next-generation research compound classified as a triple-agonist, studied for its interaction with multiple metabolic signaling pathways.

For research and educational purposes only. Not for human consumption.

American-Owned β€’ U.S.-Based Research Company
GLP-1 RT Retatrutide vial

What Is Retatrutide?

Retatrutide is a synthetic peptide investigated in research settings for its unique ability to engage three key metabolic receptors: GLP-1, GIP, and the glucagon receptor. Because it acts across multiple pathways simultaneously, it has generated significant interest in metabolic and energy-related research.

Why Researchers Are Studying Retatrutide

  • Metabolic signaling and energy balance research
  • Appetite regulation and nutrient-sensing pathways
  • Insulin sensitivity and glucose-related signaling mechanisms
  • Energy expenditure and fat-targeting metabolic pathways

Mechanism of Action

Retatrutide is categorized as a triple-agonist due to its interaction with three distinct receptors:

  • GLP-1 receptor: appetite and glucose signaling
  • GIP receptor: nutrient handling pathways
  • Glucagon receptor: energy expenditure mechanisms

Format & Storage

  • Lyophilized powder
  • Available vial sizes: 10 mg and 20 mg
  • Store in a cool, dry environment prior to reconstitution
  • Refrigerate after reconstitution

Frequently Asked Questions

Is Retatrutide a GLP-1 compound?
It interacts with the GLP-1 receptor but also engages GIP and glucagon receptors.

How is it different from traditional GLP-1 compounds?
Retatrutide is studied for multi-pathway activity rather than single-pathway focus.

Have studies shown weight-related effects?
Research discussions often focus on body composition and metabolic pathway activity.

Ready to Submit?

Review your order on the checkout page and submit your request. We will email your invoice.

Go to Checkout
Get Lucky with the Irish! Save 20% at checkout
Shop Sale β†’